Retinal neovascularization during treatment with IGF-1 for insulin resistance syndrome
- PMID: 15672252
- DOI: 10.1007/s00417-004-1093-6
Retinal neovascularization during treatment with IGF-1 for insulin resistance syndrome
Abstract
Background: Leprechaunism is a rare congenital syndrome and the most severe form of insulin resistance syndrome, with mutations in the insulin receptor gene. Recombinant human insulin-like growth factor-1 (rhIGF-1) is currently applicable to the treatment for insulin resistance syndrome by its insulin-like effect. Although IGF-1 is thought to promote tissue proliferation and neovascularization, it is uncertain how it acts on the development of diabetic retinopathy.
Methods: Interventional case report.
Results: A 12-year-old girl with leprechaunism has been treated with IGF-1 since she was 6 months old. She presented with neovascular glaucoma in the left eye, but with no serious changes in the right fundus except for tortuosity and dilatation of retinal veins. Thereafter, retinal neovascularization in the right eye developed in 6 months to form a loop-shaped vascular network in the vitreous cavity despite panretinal photocoagulation.
Conclusions: Characteristics of retinal neovascularization and clinical course suggest that IGF-1 treatment was closely associated with the development of diabetic retinopathy in this case.
Similar articles
-
Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism).Eur J Ophthalmol. 2010 Jan-Feb;20(1):224-7. doi: 10.1177/112067211002000133. Eur J Ophthalmol. 2010. PMID: 19882513
-
Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.J Clin Invest. 1993 Dec;92(6):2620-5. doi: 10.1172/JCI116877. J Clin Invest. 1993. PMID: 7504689 Free PMC article.
-
Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.J Clin Endocrinol Metab. 1998 Feb;83(2):542-9. doi: 10.1210/jcem.83.2.4602. J Clin Endocrinol Metab. 1998. PMID: 9467572
-
Mecasermin (recombinant human insulin-like growth factor I).Adv Ther. 2009 Jan;26(1):40-54. doi: 10.1007/s12325-008-0136-5. Epub 2009 Jan 28. Adv Ther. 2009. PMID: 19198769 Review.
-
[Leprechaunism caused by mutations in the insulin receptor gene].Nihon Rinsho. 2002 Feb;60(2):344-9. Nihon Rinsho. 2002. PMID: 11857924 Review. Japanese.
Cited by
-
Development of endometrial carcinoma in a patient with leprechaunism (donohue syndrome).Clin Pediatr Endocrinol. 2013 Apr;22(2):33-8. doi: 10.1292/cpe.22.33. Epub 2013 Apr 26. Clin Pediatr Endocrinol. 2013. PMID: 23990696 Free PMC article.
-
Two novel mutations identified in familial cases with Donohue syndrome.Mol Genet Genomic Med. 2014 Jan;2(1):64-72. doi: 10.1002/mgg3.43. Epub 2013 Nov 14. Mol Genet Genomic Med. 2014. PMID: 24498630 Free PMC article.
-
Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature.Int J Mol Sci. 2018 Apr 24;19(5):1268. doi: 10.3390/ijms19051268. Int J Mol Sci. 2018. PMID: 29695048 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous